MedPage Today) — Credit: B.E.L.A. butterfly children
The FDA granted the first drug approval for dystrophic epidermolysis bullosa (DEB), a topical gene therapy that treats the blistering wounds it causes, the agency announced Friday.
Comments are closed.
Type above and press Enter to search. Press Esc to cancel.